Treatment of Obsessive-Compulsive Disorder in Children

First-Line Treatment Approach

The American Academy of Child and Adolescent Psychiatry recommends cognitive-behavioral therapy (CBT) with exposure and response prevention (ERP) as the first-line treatment for obsessive-compulsive disorder (OCD) in children, either alone or in combination with selective serotonin reuptake inhibitors (SSRIs) for more severe cases 1
CBT has demonstrated larger effect sizes than pharmacological therapy, with a number needed to treat of 3 for CBT versus 5 for SSRIs, according to the International Society for Research on Child and Adolescent Psychopathology 1
The American College of Psychiatrists suggests that SSRIs are the first-line pharmacological treatment for OCD in children, with treatment maintained for at least 8-12 weeks at the maximum recommended or tolerated dose to determine efficacy 1

The American Academy of Child and Adolescent Psychiatry recommends choosing CBT when the patient/family prefers CBT to medication, OCD is without comorbid disorders requiring medication, and trained CBT clinicians are available, while choosing SSRI when the patient/family prefers medication to CBT, OCD is severe enough to prevent engagement with CBT, or the patient has comorbid disorders for which SSRIs are recommended 1
The International Society for Research on Child and Adolescent Psychopathology suggests considering combined CBT+SSRI for severe OCD cases, with monthly booster sessions for 3-6 months after initial treatment 1, 2

Family involvement is crucial for treatment success, especially for children with OCD, according to the American Academy of Child and Adolescent Psychiatry 1
The American College of Psychiatrists recommends psychoeducation about OCD should be provided to both the patient and family, and that early intervention is associated with better outcomes 1

Delaying treatment initiation, inadequate dose or duration of SSRI treatment, premature discontinuation of medication, neglecting family involvement in treatment, and failing to address comorbid conditions that may complicate treatment are common pitfalls to avoid, as suggested by the American Academy of Child and Adolescent Psychiatry 1

Combined CBT and SSRI treatment is likely more effective than SSRI alone for patients with severe OCD, those with partial response to monotherapy, and cases with significant comorbidities, according to the American College of Psychiatrists 1

Maintain the selected SSRI at the maximum recommended or tolerated dose for at least 8–12 weeks before judging efficacy. This duration is required to allow adequate therapeutic exposure in children and adolescents. 3
Continue SSRI therapy for a minimum of 12–24 months after the patient achieves remission, to sustain benefit and reduce relapse risk. 3
Longer maintenance treatment may be necessary because discontinuation is associated with a high risk of relapse; clinicians should individualize duration based on relapse risk factors. 3

Significant symptom improvement can be observed within the first 2 weeks of SSRI treatment, with the greatest incremental gains occurring early in the course. Early response provides an initial indication of drug effectiveness. 3
An early reduction in symptom severity by week 4 predicts a positive treatment response at week 12, supporting the use of early assessments to guide continuation decisions. 3

Use the Yale‑Brown Obsessive‑Compulsive Scale (Y‑BOCS) or an equivalent standardized instrument to objectively track symptom severity.
Conduct formal efficacy assessments at 2 weeks, 4 weeks, and again at 8–12 weeks to determine whether the therapeutic trial meets response criteria. 3

Approximately 50 % of pediatric patients do not achieve full response to first‑line SSRI monotherapy, highlighting the need for systematic escalation strategies. 3
For inadequate responders, consider switching to a different SSRI or increasing the dose within safety limits before adding adjunctive agents. 3
Augmentation with atypical antipsychotics (e.g., risperidone or aripiprazole) is an evidence‑supported option for patients with persistent symptoms despite optimal SSRI dosing. 3
Glutamatergic agents such as N‑acetylcysteine or memantine may be employed as augmentation strategies in treatment‑resistant cases, based on emerging data. 3